多药耐药基因PgP、ToPo-Ⅱ、GST-π与Ki-67在肺癌中的表达及其临床病理学意义  

The expression and significance of multidrug resistance genes PgP,ToPo-Ⅱ,GST-π and Ki-67 in lung cancer

作　　者：张彩兰[1,2] 刘斌[1,2,3] 杨艳丽[1] 苏勤军[1] 张登才[2] 史敏[1] 钱震[1] 董亮[1] 哈英娣[1] 

机构地区：[1]中国人民解放军兰州军区兰州总医院病理科,甘肃兰州730050 [2]兰州大学基础医学院病理研究所,甘肃兰州730050 [3]甘肃省干细胞与基因药物重点实验室,甘肃兰州730050

出　　处：《现代肿瘤医学》2013年第1期81-84,共4页Journal of Modern Oncology

基　　金：甘肃省自然科学基金资助项目(编号:096RJZA096)

摘　　要：目的:探讨耐药基因PgP、ToPo-Ⅱ、GST-π和核增殖细胞抗原Ki-67在肺癌中的表达及其临床病理学意义。方法:应用免疫组织化学(SP法)检测58例肺癌中PgP、ToPo-Ⅱ、GST-π和增殖细胞核抗原Ki-67的表达情况。结果:PgP、ToPo-Ⅱ、GST-π在58例肺癌组织中的阳性率分别为17.1%、79.1%、72.3%;其中ToPo-Ⅱ在鳞癌和小细胞癌中的表达明显高于腺癌组织(P<0.05),PgP、GST-π在三种癌中的表达无差异;三种耐药基因的共表达在淋巴结有转移中的表达明显高于无转移组(P<0.05),而与癌症类型无相关性;Ki-67的表达与三种耐药基因无明显相关。结论:肺癌的耐药与多种耐药基因蛋白介导有关,联合检测肺癌中多种耐药基因蛋白的表达,对于临床选择合理的化疗药物及防止耐药有重要意义。Objective：To explore the expression and the significance of drug resistance genes PgP,ToPo-Ⅱ, GST-π and nuclear proliferation antigen Ki -67 in lung cancer, nethods：Immunohistochemistry （SP） was used to examined the expression levels of drug resistance genes PgP,ToPo-Ⅱ, GST-π and nuclear proliferation antigen Ki -67 in 58 samples of lung cancer tissues. Results：The positive rates of PgP, ToPo-Ⅱ, GST-π in lung carci- noma were 17.1% ,79.1% ,72.3% ,the expression rate of ToPo - Ⅱ in squamous cell carcinoma and small cell lung cancer was obviously higher than in adenocarcinoma tissues （ P 〈 0.05 ）, the expression rate of PgP and GST -π had no difference ; co - expression of three markers was obvious higher in lymph node metastasis tissue than without lymph node metastasis tissue（P 〈 0.05） ;The expression rate of Ki -67 had no relation in three markers of drug resistance genes and cancer type. Conclusion ： Drug - resistence of lung cancer is related to muhidrug resistence protein, it is important to combined detect the expression of muhidrug resistence for clinically choosing reasonable chemotherapy drugs and prevent drug resistance.

关 键 词：肺癌 耐药基因p-糖蛋白(PgP) 拓扑异构酶Ⅱ(ToPo-Ⅱ) 谷胱甘肽-S-转移酶π(GST-π) KI-67 

分 类 号：R734.2[医药卫生—肿瘤]